|

MK-1084 Clinical Trials

3 actively recruiting trials across 2 locations

Pipeline

Phase 1: 1Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Merck Sharp & Dohme LLC3

Indications

  • Cancer3
  • Lung Cancer2
  • Lung Neoplasm Malignant1
  • Metastatic Solid Tumors1
  • Malignant Neoplasm1

Clermont, Florida2 trials

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

Clermont Oncology Center ( Site 0041)

Phase 1/2
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Clermont Oncology Center ( Site 0041)

Phase 2

Chicago, Illinois1 trial

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Northwestern Memorial Hospital ( Site 0002)

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.